Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Nuvectra Corpex_130966.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

 

 

  

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 28, 2018

 


 

 

 

 

Nuvectra Corporation

(Exact Name of Registrant as Specified in its Charter)


 

 

Delaware

001-37525

30-0513847

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

  

5830 Granite Parkway, Suite 1100,

Plano, Texas 75024

(Address of principal executive offices, including zip code)

 

(214) 474-3103

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 


 

   

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☒

 

 

 

 

 

 

 

Item 8.01

Other Events.

 

On December 3, 2018, Nuvectra Corporation (the “Company”) issued a press release announcing receipt of U.S. Food and Drug Administration head-only MR-conditional approval for the Company’s Algovita® Spinal Cord Stimulation system. A copy of the press release is attached hereto as Exhibit 99.1 and is being furnished, not filed, under Item 8.01 of this Current Report on Form 8-K.

 

Item 9.01

Financial Statements and Exhibits.

 

(d)

Exhibits 

  

Exhibit No.

Description

   

99.1

Press Release dated December 3, 2018.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

NUVECTRA CORPORATION

 

 

 

 

Date: December 3, 2018

/s/ Walter Z. Berger

 

 

Walter Z. Berger

 

 

Chief Operating Officer and Chief Financial Officer

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.

Description

   

99.1

Press Release dated December 3, 2018.